More specifically, CSF screening was more sensitive in examining in detecting HCG abnormalities, while serum was more sensitive to AFP elevations, indicating that although additional study may refine testing guidelines, for the foreseeable future collection of both tumor markers from CSF and serum is recommended to be continued as the GCT standard-of-care [8, 11, 13, 14, 19]. This evidence concerns the gene AFP and neoplasm.